An Outcome Analysis of Primary Membranous Nephropathy
An Observational, Longitudinal Study to Describe the Outcome, and Outcome Predictors, of Patients With Primary Membranous Nephropathy, and the Nephrotic Syndrome Treated With Rituximab, or Other Monoclonal Antibodies
Mario Negri Institute for Pharmacological Research
500 participants
Nov 29, 2024
OBSERVATIONAL
Conditions
Summary
This is an observational study intended to track the course of the primary membranous nephropathy disease in real-world clinical practice. The study will primarily assess the long-term outcomes of patients with primary membranous nephropathy in the context of advances in treatment options.
Eligibility
Inclusion Criteria4
- Adults (≥18 years old) on the day of signing informed consent.
- Diagnosis of primary membranous nephropathy
- Nephrotic syndrome (proteinuria \>3.5 g/24 hours)
- Written informed consent to the use of recorded data for research purposes.
Exclusion Criteria2
- Legal incapacity or limited legal capacity.
- Any contraindication to treatment with rituximab or other monoclonal antibody
Interested in this trial?
Get notified about updates and connect with the research team.
Locations(2)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06242327